POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
25 hedge funds and large institutions have $184M invested in POINT Biopharma Global Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 4 reducing their positions, and closing their positions.
39% more funds holding
Funds holding: 18 → 25 (+7)
1% less capital invested
Capital invested by funds: $186M → $184M (-$1.21M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$159K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$27.8K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$14.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13.2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$625K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$428K |
| 3 |
Janus Henderson Group
London,
|
-$13.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.09K |
PNT Hedge Fund Activity: Q4 2020 in Review
25 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2020, worth a combined $184M — down 0.65% from $186M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PNT positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 4 trimmed.
The largest buyer was Sigma Planning Corp, opening a new position worth an estimated $159K. The largest seller was BVF Inc, cutting an estimated $625K.
- 25 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2020, up from 18 in Q3 2020.
- Funds reported $184M of POINT Biopharma Global Inc. Common Stock stock for Q4 2020, down 0.65% quarter-over-quarter.
- 7 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +7 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2020 was Sigma Planning Corp, an estimated $159K added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2020 was BVF Inc, an estimated $625K sold.
Based on aggregated 13F filings for Q4 2020.